VRTX catalysts
Catalysts and events linked to VRTX, newest first.
VRTX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial 2026-09-24 · Up | clinical pipeline expansion into nephrology beyond core cystic fibrosis portfolio | Vertex posted Phase IIb AMPLIFIED study showing 42.7% UACR reduction and completed AMPLITUDE pivotal study enrollment. | Not recorded |
| Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD 2026-09-24 · Up | pipeline net present value addition on AMKD clinical validation | Source shows inaxaplin reduced UACR by 42.7% in Phase IIb with AMPLITUDE pivotal enrollment complete. | Not recorded |
| Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin 2026-09-24 · Up | pipeline net present value repricing on positive late-stage efficacy | AMPLIFIED study showed 42.7% UACR reduction with pivotal trial enrollment complete | Not recorded |
| Vertex reports positive Phase IIb inaxaplin results for kidney disease 2026-09-24 · Up | pipeline net present value repricing on late-stage clinical efficacy | AMPLIFIED study met primary endpoint with 42.7% UACR reduction; AMPLITUDE Phase II/III enrollment completed. | Not recorded |
| FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy 2026-09-09 · Up | co-commercialization revenue share expansion | Vertex co-develops and commercializes Casgevy alongside CRISPR Therapeutics. | Not recorded |
| CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M 2026-09-09 · Up | commercial partnership royalty and revenue sharing upside | Vertex co-develops and commercializes Casgevy globally with CRISPR Therapeutics. | Not recorded |
| CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric Label 2026-09-09 · Up | commercial collaboration revenue recognition for Casgevy partner | Vertex is the co-development and commercialization partner for Casgevy. | Not recorded |
| CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue Growth 2026-09-09 · Up | commercial revenue share on Casgevy global sales | Vertex co-commercializes Casgevy with CRISPR Therapeutics. | Not recorded |
Do these developments change your position?
Review VRTX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+CRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MVRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MVRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA ExpansionCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MVRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA ExpansionCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76MVRTX-1.51%
- 2026-09-09CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpCRSP VRTX-1.51%
- 2026-09-09CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansionCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA ExpansionCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
- 2026-09-09CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Casgevy Q2 Sales Surge 78% QoQ to $76M on Pediatric LabelCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label and Posts 78% Sequential Revenue GrowthCRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+CRSP VRTX-1.51%
- 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MCRSP VRTX-1.51%
- 2026-07-08Vertex to Acquire Crinetics for $10B at 102% Premium to Expand Rare Disease PortfolioCRNX VRTX XPH-4.28%
- 2026-07-08Vertex to Acquire Crinetics for $10B at 102% PremiumCRNX VRTX-4.28%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.